Search Results - "Del Real, Marissa"

PSCA-CAR T cell therapy in metastatic castration-resistant prostate cancer: a phase 1 trial by Dorff, Tanya B., Blanchard, M. Suzette, Adkins, Lauren N., Luebbert, Laura, Leggett, Neena, Shishido, Stephanie N., Macias, Alan, Del Real, Marissa M., Dhapola, Gaurav, Egelston, Colt, Murad, John P., Rosa, Reginaldo, Paul, Jinny, Chaudhry, Ammar, Martirosyan, Hripsime, Gerdts, Ethan, Wagner, Jamie R., Stiller, Tracey, Tilakawardane, Dileshni, Pal, Sumanta, Martinez, Catalina, Reiter, Robert E., Budde, Lihua E., D’Apuzzo, Massimo, Kuhn, Peter, Pachter, Lior, Forman, Stephen J., Priceman, Saul J.

“…Despite recent therapeutic advances, metastatic castration-resistant prostate cancer (mCRPC) remains lethal. Chimeric antigen receptor (CAR) T cell therapies…”
Get full text

Architecture of a lymphomyeloid developmental switch controlled by PU.1, Notch and Gata3 by Del Real, Marissa Morales, Rothenberg, Ellen V

“…Hematopoiesis is a classic system with which to study developmental potentials and to investigate gene regulatory networks that control choices among alternate…”
Get full text

Transcriptional establishment of cell-type identity: dynamics and causal mechanisms of T-cell lineage commitment by Rothenberg, Ellen V, Champhekar, Ameya, Damle, Sagar, Del Real, Marissa Morales, Kueh, Hao Yuan, Li, Long, Yui, Mary A

“…Precursor cell entry into the T-cell developmental pathway can be divided into two phases by the closure of T-lineage commitment. As cells decide against the…”
Get full text

CD19-Directed CAR T-Cells (CD19-CAR) Combined with Acalabrutinib Achieves Durable Remissions in Patients with Relapsed or Refractory (r/r) Mantle Cell Lymphoma (MCL) by Baird, John H., Del Real, Marissa Morales, Song, Joo Y., Shouse, Geoffrey P., Danilov, Alexey, Herrera, Alex F., Popplewell, Leslie L., Rosen, Steven T., Davis, Jennifer, Barva, Baishakhi, Chen, Lu, Kwak, Larry W., Forman, Stephen J., Budde, L. Elizabeth

“…Background: MCL is an aggressive non-Hodgkin lymphoma (NHL) subtype which remains incurable despite improvements in progression free survival with…”
Get full text

Promising Safety and Anti-Lymphoma Efficacy of Autologous Pmb-CT01 (BAFFRCAR T Cell) Therapy in a First-in-Human Phase 1 Study by Budde, L. Elizabeth, Del Real, Marissa Morales, Baird, John H., Chen, Lu, Song, Joo Y., Kambhampati, Swetha, Macias, Alan, Kim, Teresa, Dulan, Sylvia, Barva, Baishakhi, Puverel, Sandrine, Tiemann, Katrin, Cheng, Hazel Ting-Ying, Forman, Stephen J., Kwak, Larry W.

“…Introduction: CD19 chimeric antigen receptor (CAR) T cell therapy has revolutionized the treatment landscape of B cell lymphoma. However, a significant number…”
Get full text

PMB-CT01 (BAFFR-CAR T cell) therapy to examine preliminary safety and clinical responses in patients with B-cell malignancies who are ineligible for or failed CD19-directed therapy, including CD19-negative disease by Budde, Lihua Elizabeth, Del Real, Marissa, Baird, John H., Chen, Lu, Song, Joo Y, Wang, Xiuli, Kambhampati, Swetha, Macias, Alan, Kim, Teresa, Dulan, Sylvia, Barva, Baishakhi, Guan, Min, Espinosa, Ruby, Puverel, Sandrine, Tiemann, Katrin, Cheng, Hazel (Ting-Ying), Forman, Stephen J., Kwak, Larry W., Aldoss, Ibrahim

“…6534 Background: CD19-targeted therapies have shown remarkable efficacy in patients with B-cell malignancies. However, relapse with CD19 loss as a mechanism of…”
Get full text

Checkpoint Blockade in Combination with CD33 Chimeric Antigen Receptor T Cell Therapy and Hypomethylating Agent Against Acute Myeloid Leukemia by Xue, Tongyuan, Del Real, Marissa, Marcucci, Emanuela, Toribio, Candida, Setayesh, Sonia Maryam, Forman, Stephen J, Horne, David A, Budde, Lihua E

“…Acute myeloid leukemia (AML) is the most common acute leukemia in adults. The cure rate for primary AML patients is only 35% and decreases with age. Novel and…”
Get full text

Interim Results of a Phase 1/2 Study of Pembrolizumab Combined with Blinatumomab in Patients with Relapsed/Refractory (r/r) ALL by Sandhu, Karamjeet S., Macias, Alan, Del Real, Marissa, Beltran, Asuscena L., Kim, Young Sun, Zhang, Jianying, Palmer, Joycelynne, Robbins, Marjorie, Loomis, Reyna, Akhtari, Mojtaba, Aribi, Ahmed, Arslan, Shukaib, Salhotra, Amandeep, Mei, Matthew, Pourhassan, Hoda, Koller, Paul B., Amanam, Idoroenyi, Agrawal, Vaibhav, Curtin, Peter T., Spielberger, Ricardo, Pullarkat, Vinod A., Aldoss, Ibrahim, Stewart, F. Mark, Smith, Eileen P., Forman, Stephen J, Stein, Anthony S., Marcucci, Guido, Budde, L. Elizabeth

Get full text

Analysis of polyfunctionality for enhanced BAFF-R CAR T-cell therapy for hematologic malignancies by Dong, Zhengyuan, Budde, L. Elizabeth, Oh, Elizabeth, Szymura, Szymon, Anderson, Aaron, Del Real, Marissa, Cha, Soung-chul, Forman, Stephen J., Kwak, Larry W., Wang, Xiuli

“…•The polyfunctionality of CAR T cells is affected by stimulation conditions, effector-to-target ratio, antigen density, and CAR specificity.•Robust indicators…”
Get full text

Remissions of Acute Myeloid Leukemia and Blastic Plasmacytoid Dendritic Cell Neoplasm Following Treatment with CD123-Specific CAR T Cells: A First-in-Human Clinical Trial by Budde, Lihua, Song, Joo Y, Kim, Young, Blanchard, Suzette, Wagner, Jamie, Stein, Anthony S., Weng, Lihong, Del Real, Marissa, Hernandez, Rochelle, Marcucci, Emanuela, Shepphird, Jennifer K, Wang, Xiuli, Wood, Brent, Marcucci, Guido, Brown, Christine E, Forman, Stephen J.

“…The current treatment of relapsed or refractory AML is associated with low rates of complete response (CR) and considerable complications. As a result, only a…”
Get full text

Anti-IL1RAP/CD3 Bispecific Antibody (BsAb) Is a Promising Novel and Effective Therapy for Acute Myeloid Leukemia (AML) by Meng, Weixu, Del Real, Marissa, Wei, Guowei, Hernandez, Rochelle, Marcucci, Emanuela, Lin, Allen, Mcdonald, Tinisha, Zhao, Dandan, Wu, Herman, Carlesso, Nadia, Kwak, Larry W, Li, Ling, Kuo, Ya-Huei, Stein, Anthony S., Pullarkat, Vinod, Nakamura, Ryotaro, Rosen, Steven T., Forman, Stephen J., Zhang, Bin, Budde, Lihua, Marcucci, Guido

“…Despite increasing insight of the mechanisms of leukemogenesis, implementation of risk-stratification treatment strategies and use of molecular targeting…”
Get full text

Analysis of a transcriptional network involving PU.1, Notch, and Gata3 in the lymphomyeloid lineage decision during early T-cell development by Del Real, Marissa Morales

“…Hematopoiesis is a well-established system used to study developmental choices amongst cells with multiple lineage potentials, as well as the transcription…”
Get full text

Analysis of a transcriptional network involving PU.1, Notch, and Gata3 in the lymphomyeloid lineage decision during early T-cell development by Del Real, Marissa Morales

“…Hematopoiesis is a well-established system used to study developmental choices amongst cells with multiple lineage potentials, as well as the transcription…”
Get full text